Please wait a minute...
Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology)  2006, Vol. 7 Issue (12): 9-    DOI: 10.1631/jzus.2006.B0992
    
Dose-response study of spinal hyperbaric ropivacaine for cesarean section
CHEN Xin-zhong, CHEN Hong, LOU Ai-fei, LÜ Chang-cheng
Department of Anesthesia, Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
Download:     PDF (0 KB)     
Export: BibTeX | EndNote (RIS)      

Abstract  Background: Spinal hyperbaric ropivacaine may produce more predictable and reliable anesthesia than plain ropivacaine for cesarean section. The dose-response relation for spinal hyperbaric ropivacaine is undetermined. This double-blind, randomized, dose-response study determined the ED50 (50% effective dose) and ED95 (95% effective dose) of spinal hyperbaric ropivacaine for cesarean section anesthesia. Methods: Sixty parturients undergoing elective cesarean section delivery with use of combined spinal-epidural anesthesia were enrolled in this study. An epidural catheter was placed at the L1~L2 vertebral interspace, then lumbar puncture was performed at the L3~L4 vertebral interspace, and parturients were randomized to receive spinal hyperbaric ropivacaine in doses of 10.5 mg, 12 mg, 13.5 mg, or 15 mg in equal volumes of 3 ml. Sensory levels (pinprick) were assessed every 2.5 min until a T7 level was achieved and motor changes were assessed by modified Bromage Score. A dose was considered effective if an upper sensory level to pin prick of T7 or above was achieved and no intraoperative epidural supplement was required. ED50 and ED95 were determined with use of a logistic regression model. Results: ED50 (95% confidence interval) of spinal hyperbaric ropivacaine was determined to be 10.37 (5.23~11.59) mg and ED95 (95% confidence interval) to be 15.39 (13.81~23.59) mg. The maximum sensory block levels and the duration of motor block and the rate of hypotension, but not onset of anesthesia, were significantly related to the ropivacaine dose. Conclusion: The ED50 and ED95 of spinal hyperbaric ropivacaine for cesarean delivery under the conditions of this study were 10.37 mg and 15.39 mg, respectively. Ropivacaine is suitable for spinal anesthesia in cesarean delivery.

Key wordsAnesthesia      Obstetric      Cesarean section      Anesthetics local      Ropivacaine      Anesthetic techniques      Subarachnoid      Dose-response     
Received: 09 June 2006     
CLC:  R614.4  
Cite this article:

CHEN Xin-zhong, CHEN Hong, LOU Ai-fei, LÜ Chang-cheng. Dose-response study of spinal hyperbaric ropivacaine for cesarean section. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2006, 7(12): 9-.

URL:

http://www.zjujournals.com/xueshu/zjus-b/10.1631/jzus.2006.B0992     OR     http://www.zjujournals.com/xueshu/zjus-b/Y2006/V7/I12/9

[1] Li Shen, Liu-guang Song, Hong Ma, Chun-na Jin, Jian-an Wang, Mei-xiang Xiang. Tea consumption and risk of stroke: a dose-response meta-analysis of prospective studies[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2012, 13(8): 652-662.
[2] Yao-min Zhu, Zu-yi Yuan, Hui Wu, Dan-dan Zhou, Gui-xia Jing. Midazolam in rabbits terminates dysrhythmias caused by intracerebroventricular ropivacaine[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2011, 12(8): 668-676.
[3] ZHOU Yang-feng, ZHU Shao-jun, ZHU Sheng-mei, AN Xiao-xia. Anesthetic management of emergent critical tracheal stenosis[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2007, 8(7): 522-525.
[4] XIANG Yan, LI Yu-hong. Comparison of 1.5% lidocaine and 0.5% ropivacaine epidural anesthesia combined with propofol general anesthesia guided by bispectral index[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2007, 8(6): 428-434.
[5] LI Yu-hong, LOU Xian-feng, BAO Fang-ping. Dynamics of vascular volume and hemodilution of lactated Ringer’s solution in patients during induction of general and epidural anesthesia[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2006, 7(9 ): 11-.